Hangzhou HealSun Biopharm Co., Ltd. announced that it has raised CNY 200 million in a round of funding led by new investors, Shenzhen Kangzhe Pharmaceutical Co., Ltd. and China Medical System Holdings Limited on October 7, 2023. The transaction also included participation from returning investor, Hangzhou Oriental Jiafu Asset Management Co., Ltd.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.2 HKD | +1.84% | +2.86% | -47.98% |
Apr. 23 | China Medical System's Anti-Anaemia NDA Accepted in China | MT |
Apr. 23 | China Medical System Holdings Limited Announces New Drug Application of Desidustat Tablets Accepted in China | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-47.98% | 2.24B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- 867 Stock
- News China Medical System Holdings Limited
- Hangzhou HealSun Biopharm Co., Ltd. announced that it has received CNY 200 million in funding from Shenzhen Kangzhe Pharmaceutical Co., Ltd., Hangzhou Oriental Jiafu Asset Management Co., Ltd., China Medical System Holdings Limited